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Exactly controlled conditional gene expressing systems are crucial for genomic functional 
research, animal transgenesis and gene therapy.  Bacterial artificial chromosomes (BACs) 
are optimal for harboring long fragments of genomic DNA or large cDNA up to 300 kb in 
size.  Therefore, BACs are available to produce transgenic cells and animals for the func-
tional studies of genes.  However, BAC can insert DNA randomly into the host genome, 
possibly causing unpredicted expression.  We previously developed a human artificial chro-
mosome (HAC) vector from human chromosome 21 using chromosome engineering.  The 
HAC vector has several important characteristics desired for an ideal gene delivery vector, 
including stable episomal maintenance, and the ability to carry large genomic DNA con-
taining its own regulatory element, thus allowing physiological regulation of the transgene 
in a manner similar to that of the native chromosome.  In this study, we develop a system 
fusing BAC library and HAC technology together to allow tight control of gene expression. 
This system enables BAC to be cloned into the defined locus on the HAC vector by the Cre/
loxP system.  In addition, the genome in the BAC is possible to be engineered freely by the 
BAC recombineering technology.  This system is a highly efficient tool for the rapid genera-
tion of stringently controlled gene expression system on the HAC vector.
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The development of genomic functional studies, 
transgenic animal production and gene therapy 
requires stringently controlled gene expression 
systems.  Bacterial artificial chromosomes (BACs) 
have become important tools in functional genom-
ics (Brune et al., 2000; Heintz,2001; Sparwasser 
and Eberl, 2007; Tunster et al., 2011).  BACs have 
made genomic fragments from humans, mice and 
many other species available through public ge-
nomic databases (O’Connor et al., 1989; Shizuya 
et al., 1992; Osoegawa et al., 2000).  pBACe3.6 
is used as a backbone vector in the majority of 
currently available BAC libraries (Frengen et 
al., 1999).  Specific BACs are readily obtainable 
from several bioresource centers (e. g., Children’s 
Hospital Oakland Research Institute).  As a re-
sult, the tedious screening for genomic DNA 
clones in complex libraries is reduced.  Therefore, 
BACs have greater convenience in handing over 
other large cloning vectors like P1 phage-derived 
Abbreviations: AmpR, ampicillin-resistance; BAC, bacterial artificial chromosome; CmR, chloramphenicol-resistance; 
HAC, human artificial chromosome; HPRT, hypoxanthine phosphoribosyl transferase; IL, interleukin; LB, lysogeny broth; 
PAC, P1 phage-derived artificial chromosome; SLG, stable luciferase green; SLR, stable luciferase red; SOC, super opti-
mal broth with catabolite regression; ZeoR, zeocin-resistance 
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artificial chromosomes (PACs) and yeast artificial 
chromosomes.  BACs cover average 100- to 300-
kb genomic DNA and so most mammalian genes 
can be encompassed by a single BAC.  Given their 
large size, BACs encode the complete open reading 
frame and most regulatory sequences, which reca-
pitulate the regulation of endogenous genes much 
better than shorter transgenes (Yang et al., 1997). 
In addition, a homologus recombination system 
was developed that requires only short homology 
arms and enables the full range of BAC modifica-
tions to be quickly and easily engineered in Es-
cherichia coli (E. coli) (Zhang et al., 1998; Muyrers 
et al., 1999).  This BAC engineering methodology 
is now termed “BAC recombineering” (Yu et al., 
2000; Copeland et al., 2001) and includes a broad 
range of applications including subcloning via gap 
repair (Zhang et al., 2000), point mutagenesis in 
BACs (Muyrers et al., 2000), high throughput DNA 
engineering (Sarov et al., 2006; Poser et al., 2008) 
and a variety of other, often complex, applications. 
Furthormore, BAC transgenic mice expressing a 
variety of reporters (Gong et al., 2003; Lobo et al., 
2006) or epitope tagged-proteins (Bateup et al., 
2008) driven by specific promoters become widely 
used in various in vivo functional applications. 
Because of these advantages, BACs have been used 
for transgenesis in higher model cells and organ-
isms.  To produce a target BAC transgene expres-
sion cells, random integration of foreign DNA is 
frequently used.  However, the expression of BAC 
transgene can not only be affected by positional 
effects at the insertion site of the host genome but 
also by the number of copies inserted (Gong et al., 
2003; Alexander et al., 2004; Heaney and Bronson, 
2006; Chandler et al., 2007; Le et al., 2010).  As a 
result, the expression level of genes varies greatly 
in the obtained clones.
 Human artificial chromosomes (HACs) have 
several advantages over conventional gene delivery 
systems (Larin and Mejia, 2002; Basu and Wil-
lard, 2006).  We recently developed HAC vectors 
from human chromosome 21 by deleting all of the 
endogenous genes (Kazuki et al., in press).  Like 
natural chromosomes, the HAC vector has the 
capacity to replicate and segregate freely from the 
host genome.  Therefore, the HAC vector can avoid 
the disruption of the host genome by transgene in-
sertion (Pravtcheva and Wise, 1995).  In addition, 
as reported previously, the HAC vector enables 
stable expression of the inserted gene, and is not 
affected by position in the genome (Katoh et al., 
2004; Kakeda et al., 2005; Kazuki et al., in press). 
The HAC vector is a powerful gene delivery vector 
capable of carrying large genes such as the dystro-
phin gene (2.4 Mb) (Oshimura and Katoh, 2008; 
Hoshiya et al., 2009; Kazuki et al., 2010).  Con-
ceptually and experimentally, any circular DNA 
such as BACs can be inserted into the HAC vector. 
Therefore, we considered that a more precise evalu-
ation of large DNA inserts for genetic complemen-
tation should be possible by incorporating the BAC 
system into the HAC vector.  Site-specific insertion 
of BAC into the HAC vector may eliminate un-
wanted position effects caused by the random in-
tegration of exogenously introduced DNA.  In this 
study, we describe the generation of modified BAC 
by the BAC recombineering for their introduction 
into the defined locus on the HAC vector by the 
Cre/loxP system.  Also, the genome of interest in 
the BAC is possible to be engineered by the BAC 
recombineering.
 
 
Materials and Methods
 
Vector construction
 
The modification cassette vector I for engineering 
of the genome on the BAC was constructed as fol-
lows.  RP11-67L14 (cloned in the pBACe3.6 vec-
tor, GenBank accession number: AC079753) was 
obtained from Invitrogen (Carlsbad, CA) and used 
as a model for BAC modification.  As a gene of 
interest, the coding sequence of human interleukin 
(IL)-1  was contained in the BAC.  Fragment of the 
genome specific homology arms to target the cas-
sette into the start codon of the genome in the BAC 
was amplified by blunt PCR from RP11-67L14 us-
ing the primers IL-1  hm F and IL-1  hm R.  This 
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PCR product was cloned into the pSTblue1 blunt 
vector (Novagen, Madison, WI), creating pIL-1  
hm vector.  There was an internal NcoI restriction 
site within the IL-1  insert which is the ATG start-
site of the first exon of the IL-1  genome.  The 
reporter gene of interest (stable luciferase green; 
SLG) and an ampicillin-resistance (AmpR) gene 
were amplified by PCR from the pSLG test (Toyobo, 
Osaka, Japan) using the primers SLG-Amp F and 
SLG-Amp R.  The PCR product was digested with 
NcoI and cloned into the equivalent site of pIL-1  
hm vector, creating the modification cassette vector 
I.  Sequence and orientation of the genome specific 
homology arms, SLG gene and an AmpR gene were 
confirmed by DNA sequencing and restriction en-
zyme pattern analysis.
 The modification cassette vector II was con-
structed using the Multisite Gateway kit (Invitrogen) 
as previously described (Sasaki et al., 2004; Sone et 
al., 2008).  The PCR fragments for loxP-3' HPRT, 
a zeocin-resistance (ZeoR) gene and G3PDH pro-
moter flanked by the appropriate gateway attB sites 
were created.  V901-3'HPRT-loxP (Kazuki et al., 
in press) was used as a template for loxP-3' HPRT 
amplification with primer pair B5- loxP-3' HPRT-
B4 F and B5- loxP-3' HPRT-B4 R.  The ZeoR gene 
was amplified from plasmid containing a ZeoR 
gene using the primers B4r-zeocin-B3r F and B4r-
zeocin-B3r R.  Human G3PDH promoter (GenBank 
accession number:  AY340484 region 473–1974 bp) 
was amplified with primer pair B3-G3PDH-B2 F 
and B3-G3PDH-B2 R.  The gateway attB-flanked 
PCR product was recombined with a donor vector 
containing the corresponding gateway attP signals 
in a BP reaction to generate an entry clone.  Ap-
proximately 150 ng of PCR fragment and a donor 
vector (pDONR 221 P5-P4, pDONR 221 P4r-P3r 
or pDONR 221 P3-P2) were mixed with 2 μL of 
BP clonase II enzyme mix, and adjusted to 10 μL 
with TE buffer.  The mixture was then incubated at 
25˚C for 1 h to create 3 entry clones (pENTR L5-
loxP-3' HPRT-L4, pENTR R4-zeocin-R3, pENTR 
L3-G3PDH promoter-L2).  After the BP reac-
tion, the enzymes were inactivated by treatment 
with proteinase K for 10 min at 37˚C.  Competent 
Mach1 T1R E. coli (Invitrogen) was used according 
to the supplier’s instruction.  After transformation, 
the cell solution was diluted with super optimal 
broth with catabolite regression (SOC) medium 
and incubated at 37˚C for 1 h.  The transformation 
reactions were then spread onto lysogeny broth (LB) 
agar plates containing 50 μg/mL kanamycin and 
incubated for 14 h at 37˚C.  The sequence of these 
pENTRs was confirmed by DNA sequencing.  The 
destination vector (pSLR-BAC hm DEST) con-
tained the R1-ccdB-CmR-R2 cassette (Invitrogen), 
homology arms of BAC and a stable luciferase red 
(SLR) gene.  pBACe3.6 (GenBank accession num-
ber: U80929) is used as a backbone vector for hu-
man RPCI-11 BAC library.  Regions 4205–4793 bp 
and 4946–5833 bp of pBACe3.6 were used as BAC 
homology arms and cloned into the pGEM-T vec-
tor (Promega, Madison, WI), creating pBAC hm T 
vector.  This vector contained KpnI and XbaI cleav-
age sites in exchange of original loxP site located 
in the pBACe3.6 region 4831–4864 bp.  The R1-
ccdB-CmR-R2 cassette was ligated into the pSLR 
test (Toyobo), creating pSLR DEST.  To construct 
the destination vector containing a toxic ccdB gene, 
ccdB survival competent cells (Invitrogen) were 
used for propagation according to the supplier’s 
instruction.  After transformation, the cell solution 
was diluted with SOC medium and incubated at 
37˚C for 1 h.  The transformation reactions were 
then spread onto LB agar plates containing 12.5 
μg/mL chloramphenicol and incubated for 18 h at 
37˚C.  The R1-ccdB-CmR-R2 cassette and the SLR 
gene were digested from pSLR DEST with KpnI 
and SacI (blunted).  This fragment was cloned into 
the KpnI and XbaI (blunted) sites of pBAC hm T 
vector, creating a pSLR-BAC hm DEST.  Sequence 
and orientation of this vector was confirmed by 
DNA sequencing and restriction enzyme pattern 
analysis.  Three entry clones and pENTR L1-pLac-
lacZ -R5 (Invitrogen) were recombined with a 
pSLR-BAC hm DEST to generate the modification 
cassette vector II.  Before this reaction, the pSLR-
BAC hm DEST was linearized at the BssHII site, 
between a ccdB gene and a chloramphenicol-
resistance (CmR) gene.  Around 20 ng of each entry 
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clone and 80 ng of destination vector were mixed 
with 2 μL of LR clonase II Plus enzyme mix, and 
made up to 10 μL with TE buffer.  The mixture 
was then incubated at 25˚C for 16 h.  After this 
reaction, the enzyme was inactivated by treatment 
with proteinase K for 10 min at 37˚C.  Competent 
Mach1 T1R E. coli was used for transformation. 
Following transformation, the cell solution was di-
luted with SOC medium and incubated at 37˚C for 
1 h.  The transformation reactions were then spread 
onto LB agar plates containing 50 μg/mL ampicil-
lin and 25 μg/mL zeocin.  These plates were incu-
bated for 14 h at 37˚C.  The modification cassette 
vector II carried the homology arms of pBACe3.6 
and the non-functional loxP-3' HPRT for targeting 
the HAC vector.  Cre recombinase-catalyzed inte-
gration required a functional HPRT gene.
 
 
 
BAC recombineering
 
A homologous recombination-proficient E. coli 
strain (DY380) was used for the BAC recombineer-
ing.  For BAC modification, overnight cultures con-
taining the BAC were grown from single colonies, 
diluted 10-fold in LB medium, and grown to an op-
tical density at 600 nm of 0.4 to 0.6 at 32˚C.  Fifty-
milliliter cultures were then induced for the expres-
sion of recombineering factors by shifting the cells 
to 42˚C for 15 min followed by chilling on ice for 
10 min.  Cells were then centrifuged for 5 min at 
5500 × g at 4˚C and washed with 10 mL of ice-cold 
1 mM HEPES 2 times.  Cells were then resuspend-
ed in 100 μL of ice-cold 1 mM HEPES and elec-
troporated.  Cell transformation was performed by 
electroporation of 1 μg linear DNA into 100 μL of 
ice-cold competent cells in cuvettes (0.1 cm) using 
a Bio-Rad gene pulser set at 1.75 kV, 25 μF with 
a pulse controller set at 200 ohms.  One milliliter 
of SOC medium was added after electroporation. 
Cells were incubated at 32˚C for 1 h with shaking 
and spread on appropriate selective agar media.
 
 
 
PCR analyses
 
PCR analyses were carried out using standard 
techniques.  The primer pairs used for confirmation 
of the IL-1  seque nce were IL-1  1S/IL-1  3000 
AS, IL-1  2611 S/IL-1  5180 AS, IL-1 4031 S/
IL-1  7151 AS and IL-1  8051 S/IL-1  11332 AS. 
The primer pairs used for confirmation of BAC 
recombination of the modification cassette I were 
amp2500 S and IL-1  12100 AS, along with IL-1  
10930 S and slg200 AS. 
 The primer pairs utilized for detection of 
BAC recombination of the modification cassette 
II were SLR 1650 S and BACe3.6 5839 AS, along 
with BACe3.6 4168 S and LacZ 770 AS.
 
 
Results
 
Construction of the modification cassette 
vectors
 
BACs contain all of the endogenous control ele-
ments in their natural expression of the gene of 
interest and therefore almost always recapitulate 
all of the endogenous control mechanisms, includ-
ing alternative splicing.  BAC libraries based on 
pBACe3.6 have now been generated from various 
species (Table 1) and used for reporter assay of 
gene expression.  The modification cassette vector I 
was created for engineering of the genome of inter-
est on the BAC.  This vector consists of 3 regions; 
i) the region encoding the reporter gene such as a 
fluorescent protein gene and a luciferase gene (SLG 
gene in our study), ii) AmpR gene and iii) homol-
ogy arms (A' and B') to target the cassette into the 
start codon of chosen genome on the BAC (Fig. 1a). 
The homology arms were obtained by PCR from 
a BAC containing the target genome.  In our cur-
rent study, we used a BAC clone RP11-67L14 as a 
recipient for BAC modification.  As a gene of inter-
est, the coding sequence of IL-1  was contained 
in the BAC.  The primers were designed to target 
precisely the cassette downstream of the IL-1  start 
codon (Table 2).
 In attempts to clone BAC into the HAC vec-
tor, the modification cassette vector II was con-
structed.  This vector carried a loxP sequence and 
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the 3' hypoxanthine phosphoribosyl transferase 
(HPRT) sequence.  The HAC vector used was 
21HAC1 containing the 5' HPRT-loxP site (Kazuki 
et al., in press).  The HPRT gene expressed in the 
HAC vector conferred HAT-resistance after site-
specific recombination with the Cre/loxP system. 
The modification cassette vector II consists of 
5 regions; i) loxP-3' HPRT region for introduc-
ing BAC into the HAC vector, ii) ZeoR gene, iii) 
lacZ  gene which contributed for selection in E. 
coli, iv) G3PDH promoter-SLR region which is 
used as a marker in the mammalian cells because 
of its convenience for luciferase expression and v) 
homology arms (C' and D') to target the cassette 
into the pBACe3.6 region.  The homology arms are 
obtained by PCR from pBACe3.6 (Table 2).  The 
modification cassette vector II was constructed in 
E. coli using the Multiple Gateway system, which 
is useful in high-throughput construction of plas-
mids carrying multiple DNA sequences (Sasaki et 
al., 2004; Sone et al., 2008).  The PCR fragments 
for loxP-3'HPRT, ZeoR gene and G3PDH promoter 
contained the appropriate gateway attB sites (Table 
2).  The 3 fragments were recombined into 3 differ-
ent donor vectors (pDONR221 P5-P4, pDONR221 
P4r-P3r, pDONR221 P3-P2) to create 3 entry 
clones (pENTR L5- loxP-3'HPRT-L4, pENTR 
R4-zeocin-R3, pENTR L3-G3PDH promoter-L2) 
(Fig 1b).  DNA sequencing showed that 95.0% of 
kanamycin-resistant E. coli transformant colonies 
were correctly targeted.  These 3 pENTR vectors, 
a pENTR L1-pLac-lacZ -R5 and a pSLR BAC hm 
DEST were mixed in the presence of LR clonase 
enzyme to generate the modification cassette vector 
II (Fig. 1c).  A recombination event would incor-
porate the lacZ  gene and the ZeoR gene, resulting 
in a blue colony which resistances to ampicillin 
and zeocin.  Unrecombined plasmid would result 
Table 1.  A list of BAC libraries constructed in the pBACe3.6 
 
Species DNA origin Average   Coverage Total  Site of construction
    insert size  clones
   (kb)
 
Human Human male 174 25.3X 437,034 RPCI (RPCI-11)
 Human female 166 21.8X 398,590 RPCI (RPCI-13)
Monkey Chimpanzee (Pan troglodytes) male 157 3.5X 68,721 RPCI (RPCI-43)
 Lemur (Lemur catta) 174 6.1X 106,156 LBNL (LBNL-2)
 Dusky titi (Callicebus moloch) 176 9.4X 159,667 LBNL (LBNL-5)
 Baboon (olive) male 175 10.4X 180,004 RPCI (RPCI-41)
Cow Bovine male 164 11.9X 216,439 RPCI (RPCI-42)
Dog Canine (Doberman Pinscher) male 155 8.1X 157,255 RPCI (RPCI-81)
Rabbit White rabbit (Oryctolagus cuniculus) 175 7.0X 120,804 LBNL (LBNL-1)
Hamster Chinese hamster ovary (Cricetulus Griseus) 158 5.4X 110,592 RPCI (RPCI-99)
Rat Rat (Brown Norway) male 150 11.4X 228,313 RPCI (RPCI-32)
Mouse Mouse (129S6/SvEvTac) female 154 10.9X 211,953 RPCI (RPCI-22)
 Mouse (MSM/Ms) male 125 10.0X 220,000 RIKEN BRC
 Mouse (C57BL/B6J) female 197 11.2X 180,396 RPCI (RPCI-23)
 Mouse (C57BL/B6N) male 128 2.6X 65,280 RIKEN BRC
 Mouse (129S7/SvEvBrd-Hprtb-m2) male – – 168,192 Sanger (Sanger-bMQ)
Insect Drosophila melanogaster 165 22X 17,540 RPCI (RPCI-98)
 Silkworm (Bombyx mori) 159 41.3X 147,456 RPCI (RPCI-96)
Worm Ceanorabditis briggsea – – 36,864 RPCI (RPCI-94)
Yeast Schizosacharomyces pombe 166 – 3,018 RPCI (RPCI-104)
 
LBNL, Lawrence Berkeley National Laboratory; RIKEN BRC, RIKEN BioResource Center; RPCI, Roswell Park Can-
cer Institute.
Note that this table is not an exhaustive listing of all BAC libraries and primarily lists those from the Children’s Hospital 
Oakland Research Institute and others that are publicly available.
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Fig. 1.  Generation of BAC modification cassette vectors. 
 a: The structure of the modification cassette vector I for engineering of the 
genome on the BAC.  Features of the modification cassette vector I include 
genome homology arms (A' and B') that are identical to sequences A and 
B in the target genome for homologous recombination, and a modification 
cassette (SLG-AmpR) that carries the reporter gene to be inserted into the 
genome. 
b: Construction of entry clones (pENTRs) from gateway attB-flanked PCR 
products and donor vectors (pDONRs). 
c: Construction of the modification cassette vector II from 4 entry clones and 
a destination vector (pSLR-BAC hm DEST).  Features of the modification 
cassette vector II include:  pBACe3.6 homology arms (C' and D') that are 
identical to sequences C and D in the pBACe3.6, and the non-functional 
loxP-3' HPRT for targeting the HAC vector.  
AmpR, ampicillin-resistance
BAC, bacterial artificial chromosome
CmR,  chloramphenicol-resistance
HAC,  human artificial chromosome
KmR,  kanamycin-resistance 
IL,  interleukin 
SLG, stable luciferase green
SLR,  stable luciferase red
ZeoR, zeocin-resistance 
attP4r attP3rccdB CmR 
R
 
attP3 attP2ccdB CmR  
R
 
attP5 attP4ccdB CmR 
R
 
KmR  KmR  KmR  
pDONR221 P5-P4 pDONR221 P4r-P3r pDONR221 P3-P2
pENTR R4-Zeocin-R3 pENTR L3-G3PDH promoter -L2
a
c
attR1 attR2ccdB CmR 
pSLR BAC hm DEST
PCR
product
attB5 attB4loxP-3' HPRT attB4r attB3r attB3 attB2G3PDH promoter
R
KmR  
pENTR L5-loxP 3' HPRT-L4
attL5 attL4loxP-3' HPRT
R
 
KmR  
attR4 attR3
R
 
KmR  
attL3 attL2G3PDH promoter
pENTR L3-G3PDH promoter -L2
R
 
KmR  
attL3 attL2G3PDH promoter
pENTR L1-pLac-LacZα-R5
R
 
KmR  
attL1 attR5pLac-LacZα
pENTR R4-Zeocin-R3
R
 
KmR  
attR4 attR3
R
KmR  
pENTR L5-loxP 3' HPRT-L4
attL5 attL4loxP-3' HPRT
D' C' 
b
SLG
Modification cassette vector I
B' A' AmpR
SLR
attB1 attB5pLac-LacZα attB4loxP-3' HPRT attB3 attB2G3PDH promoter D' SLRC' 
Modification cassette vector II
ZeoR
ZeoR
ZeoR
ZeoR
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in a white colony.  As a result, almost all colonies 
were blue and had the AmpR and ZeoR.  Twenty-
four of the resulting blue colonies were analyzed 
by restriction enzyme pattern analysis, and 10 of 
these colonies had the expected recombinant bands 
(41.6%).  Plasmid DNA extracted from 2 of these 
colonies was sequenced in the area of the recom-
bination junction.  All had the precise expected 
crossover event.
BAC modifications
 
We tested the activation and efficiency of BAC 
modification system for the HAC vector.  The mod-
ification cassette I was targeted to the start codon 
locus of IL-1  carried on a BAC clone RP11-67L14 
(Fig. 2a).  The purpose was to create a BAC trans-
gene that expresses reporter genes in the control of 
target genome for use in genomic functional stud-
ies.  RP11-67L14 was electroporated into DY380 
cells, and 13 chloramphenicol-resistant colonies 
were selected.  To determine the transfer of the 
BAC, we employed PCR analysis.  Using the ap-
propriate primers (IL-1  11041 S/IL-1  11851 AS) 
(Table 2), the expected amplicon was detected in 11 
of 13 colonies (84.6%).  The modification cassette 
I was released from the modification cassette vec-
tor I by EcoRI digestion and used for BAC recom-
bineering.  DY380 cells carrying the BAC were 
then shifted to 42°C to induce recombination.  The 
cells were then electroporated with the modification 
cassette I, and the ampicillin and chloramphenicol-
resistant colonies were selected.  Approximately, 
500 double resistant colonies were obtained.  No 
Table 2.  The PCR primers used in this study
 
         Primer
 IL-1  hm F
IL-1  hm R
SLG-Amp F
SLG-Amp R
B5-loxP-3' HPRT-B4 F
B5-loxP-3' HPRT-B4 R
B4r-zeocin-B3r F
B4r-zeocin-B3r R
B3-G3PDH-B2 F
B3-G3PDH-B2 R
amp2500 S
IL-1  12100 AS
IL-1  10930 S
slg200 AS
SLR1650 S
BACe3.6 5839 AS
BACe3.6 4168 S
LacZ 770 AS
IL-1  1 S
IL-1  3000 AS
IL-1  2611 S
IL-1  5180 AS
IL-1  4031 S
IL-1  7151 AS
IL-1  8051 S
IL-1  11332 AS
Amp, ampicillin; BAC, bacterial artificial chromosome; HPRT, hypoxanthine phosphoribosyl transferase; IL, interleukin; 
SLG, stable luciferase green; SLR, stable luciferase red. 
  Sequence (5'–3')
 GCC AGG TGT AAT ATA ATG CTT ATG ACT CGG
TGC AAA CAG CCT GCC TCT CAA AGC TGC CTG
CCA AAC TCA TCA ATG TAT CTT ATC ATG TCT GGA TC
GAT CCA TGG ATC TTT TCT ACG GGG TCT GAC GCT CAG TGG AAC G
GGG GAC AAC TTT GTA TAC AAA AGT TGA GAG CCT TCA ACC CAG TCA GCT CCT TC
GGG GAC AAC TTT GTA TAG AAA AGT TGG GTG GGC GCG CCA GGC TGG TTC TTT CCG CCT CAG
GGG GAC AAC TTT TCT ATA CAA AGT TTG CGC ATG CGG ACA AAC CAC AAC TAG AAT GCA GTG
GGG GAC AAC TTT ATT ATA CAA AGT TGT GTG TCA GTT AGG GTG TGG AAA GTC CCC AGG
GGG GAC AAC TTT GTA TAA TAA AGT TGG GTC AGG GAC TGG AGT CCT GTG GGT GC
GGG GAC CAC TTT GTA CAA GAA AGC TGG GTA GCC TTC AGG CCG TCC CTA GCC TCC CGG GTT TC
AGC TGA ATG AAG CCA TAC CAA ACG ACG AGC
ATA CCA TGG CAT CAA AGT GGC CCA GAA CTC
GAG TCT CTC TGT CTC TCT GCC TCT TTG TG
ACC TCC TCG GTG TGG GCG TCG ATC AGG GCC
CCG AAA GGC CCA ACA GGC AAG CTG ATG AGA
AAC TTC TGT GCT TAA AAC GTC ATC TGC ATC
TCA CTT CGC AGT GCC GCA AGC CAA AGG CAA
GCA GGC ATG CAA GCT TGG CGT AAT CAT GGT
CAC AAA GTG AGC TTG AAA TGA ATT CCC AGG
TGT GCA CCC TCA GTG CCT GGG TGG CTT ACC
TCC CTT AGG GGC AGG ATT GAC ACA TCC AAG
TCC ATT TCT GCT GGC CCA CTT CCC TGT CTC
CCA CCC ATT CCT CGT TAC AAT GTC AAT GCC
GGA ATG GGC ACT ATG ATT TTT ATC ATA TCG
CAT TGC CCC ATG GCT CCA AAA TTT CCC TCG
GGC TGC TTC AGA CAC CTG  TGT AAA AAG GAG
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AmpR, ampicillin-resistance
BAC, bacterial artificial chromo-
some
CmR, chloramphenicol-resistance
HAC, human artificial chromosome
HPRT, hypoxanthine phosphoribosyl 
transferase
HygR, hygromycin-resistance
IL,  interleukin
SLG, stable luciferase green
SLR,  stable luciferase red
ZeoR,  zeocin-resistance 
Fig. 2.  Strategy of BAC modification and introduction into the HAC vector. 
 a: The 1st step of the process is the homologus recombination of the BAC using the modification cassette I.  It occurs 
by crossing over between the homology arms and the genome in the BAC.  In this case, recombination between A 
B and A' B' results in incorporation of the modification cassette sequences into the genome to yield the mBAC1. 
The second step of the process is the homologus recombination of the mBAC1 using the modification cassette II.  It 
occurs by a second homologous recombination event that occurs between C D and C' D' of the mBAC1. Recombi-
nation yields the precisely modified BAC2 (mBAC2), with the modification cassette II inserted at the correct posi-
tion in the BAC.  This modified BAC carries loxP-3'HPRT region for introduction to the HAC vector. 
b: Construction of the HAC vector containing the modified BAC using Cre/loxP system. 
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colonies were obtained from uninduced cells.  PCR 
analysis of 7 selected colonies using the primers 
(IL-1 10930 S/slg200 AS and amp2500 S/IL-1  
12100 AS) (Table 2) that flanked the targeted locus 
indicated that all colonies were correctly targeted 
(100%).  This recombineering efficiency was very 
high.  This means that SLG-AmpR cassette was 
recombined into the 1st ATG locus of IL-1  carried 
on a RP11-67L14.  This BAC was termed modified 
BAC1 (mBAC1).
 Next, to insert the loxP-3'HPRT region into 
the mBAC1, the modification cassette II was tar-
geted to the chosen site on the pBACe3.6 (Fig. 2a). 
This modification cassette II was released from the 
modification cassette vector II by SacII-NdeI di-
gestion and used for recombineering.  DY380 cells 
carrying the mBAC1 were then shifted to 42˚C. 
The cells were then electroporated with the modi-
fication cassette II, and the ampicillin-, chloram-
phenicol- and zeocin-resistant colonies were 
selected.  As a result, 34 colonies were obtained. 
These colonies were blue and had the AmpR, CmR 
and ZeoR.  PCR analysis of 11 selected colonies 
using the primers (SLR1650 S/BACe3.6 5839 AS 
and BACe3.6 4168 S/LacZ 770 AS) (Table 2) that 
flanked the targeted locus indicated that 6 colonies 
were correctly targeted (54.5%).  This indicates 
that the modification cassette containing the loxP-
3'HPRT region was inserted into the mBAC1.  This 
BAC was termed modified BAC2 (mBAC2).  Fi-
nally, mBAC2 had the correct insert genome as de-
termined by PCR analysis using primers (IL-1  1 
S/IL-1  3000 AS, IL-1  2611 S/IL-1  5180 AS, IL-
1  4031 S/IL-1  7151 AS and IL-1  8051 S/IL-1  
11332 AS) (Table 2).  This modified BAC carries a 
loxP and 3'HPRT sequence, and has the capacity of 
site-specific insertion into the HAC vector via Cre/
loxP system (Fig. 2b).
  
 
Discussion
 
In this study, we constructed a BAC modification 
system for the HAC vector which can be used to 
integrate the reporter gene into a chosen region of 
the genome and the loxP-3'HPRT cassette into a 
specific site in the BAC.  Our system will enable 
insertion of large DNA fragments of interest at 
predetermined locations in the HAC vector.  This 
system may thereby allow avoidance of the position 
effects and actualize intrinsic expression of trans-
genes.  Furthermore, BAC libraries have now been 
generated from several species.  Table 1 lists BAC 
libraries that were constructed in the pBACe3.6. 
These ready-made genomic BAC libraries can be 
loaded onto the HAC vector using our system.
 Our system is based on BAC recombineering. 
The recombination activity was assessed in using 
the modification cassettes I and II.  The results of 
these recombination assays indicated that BAC 
recombineering conferred high recombination ac-
tivity (cassette I; 100%, cassette II; 54.5%).  This 
technology may be suited for cassette exchange 
reactions in the BAC.  In addition, BACs can be 
modified rapidly in vitro, with a construction time 
of less than 2 weeks in this study.  As the HAC 
vector contains the 5' HPRT-loxP, the modified 
BAC could be introduced into the HAC vector.  By 
introducing all candidate BAC clones into the same 
genomic locus, site-specific integration of large 
genomic clones can be used to streamline the po-
sitional cloning and transfer of genes into various 
mammalian cells.  This ability of BAC-HAC sys-
tem will reduce the number of subclones and trans-
genic cells required to determine which clones con-
tain the target gene.  This system will allow gen-
eration of an isogenic series of assays that would be 
expected to display comparable expression profiles 
due to their placement in identical genomic and 
cellular backgrounds.  In addition, the HAC vector 
can be used for the generation of transgenic ani-
mals (trans-chromosomic mice) for the functional 
analysis of a desired gene in mice (Hoshiya et al., 
2009; Kazuki et al., in press).  Therefore, our BAC-
HAC system could provide significant advantages 
for comparing the gene function of species at a spe-
cific locus, and allow for a better understanding of 
the correlation between cell (in vitro) and animal (in 
vivo).  These types of assays are difficult to achieve 
with current techniques that rely on random inte-
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gration of the target genes.
 In summary, our system enables BAC modifi-
cations for the HAC vector to be quickly and easily 
engineered.  The use of BAC clones in conjunction 
with the HAC vector opens the way to many addi-
tional applications, especially for investigating gene 
function, gene therapy and animal transgenesis.
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